Lee Schwartzberg

[Lee Schwartzberg @OncSTATdoc]

@bfrist Deepest thanks Bill, for being the voice of reason and action.

[Lee Schwartzberg @OncSTATdoc]

@agrothey Morphine and bourbon

[Lee Schwartzberg @OncSTATdoc]

Her2 + patients consistently doing better than expected. Intensity of anti Her2 therapy should probably be individualized. #ASCO2017

[Lee Schwartzberg @OncSTATdoc]

Basch reports 5 month median survival improvement with electronic patient report symptoms. If it was a drug, everyone would want it!#ASCO17

[Lee Schwartzberg @OncSTATdoc]

The Patient Care Monitor, an electronic patient engagement system, has 15 yrs of development, validation & implementation experience #ASCO17

[Lee Schwartzberg @OncSTATdoc]

Electronic symptom monitoring improves survival by 5 months. If this was a drug, everyone would be using.

[Lee Schwartzberg @OncSTATdoc]

Electronic patient symptom monitoring improves survival based on RCT compared to standard monitoring. Survival improved 5 months #asco17

[Lee Schwartzberg @OncSTATdoc]

PD-1 antibodies in TNBC in desperate need of better biomarker. Huge benefit for a tiny fraction of patients. Need to figure out why #ASCO17

[Lee Schwartzberg @OncSTATdoc]

Oncotype DX prospectively validated for excellent prognosis in low risk patients in @NEJM

[Lee Schwartzberg @OncSTATdoc]

SOFT shows benefit for OFS+ EXE over TAM alone in premenopausal women getting chemo. A new std in this group. Best in women < 35 yo

[Lee Schwartzberg @OncSTATdoc]

TNT Trial supports testing all TNBC for BRCA mutation and treat with 1st line Carboplatin if +. Impressive PFS in this group #SABCS14

[Lee Schwartzberg @OncSTATdoc]

Geparsepto showed increased pCR rate for nab- PAC compared to solvent PAC but more neuropathy. Looks particularly strong in triple negatives

[Lee Schwartzberg @OncSTATdoc]

PAM 50 will be increasingly important in determining subtype . Lum A and LumB show differential benefit to AIs

[Lee Schwartzberg @OncSTATdoc]

Lobular Ca has distinct genomic profile from IDC. HER Axis surprisingly mutated in 8%- possible therapeutic target. #SABCS14

[Lee Schwartzberg @OncSTATdoc]

Pi3K inhibitor shows modest benefit and substantial toxicity added to fulvestrant in pretreated ER+ MBC. Mutation was not marker #SABCS14

[Lee Schwartzberg @OncSTATdoc]

ALTTO reduces the enthusiasm for neoadjuvant pCR as a good surrogate marker predicting long term DFS and OS outcomes.

[Lee Schwartzberg @OncSTATdoc]

With most HER2+ pts now doing well with chemo + tras, as in ALTTO & BETH, which subgroups might really benefit from dual HER2 blockade?

[Lee Schwartzberg @OncSTATdoc]

ALTTO did not show benefit for addition of lapatinib to trastuzumab in early stage HER2+ breast cancer, although there is a trend for combo

[Lee Schwartzberg @OncSTATdoc]

Expanded RAS analysis will be done and if it confirms PRIME, PEAK and FIRE-3 could favor anti -EGFR Ab + chemo as superior for all-RAS wt.

[Lee Schwartzberg @OncSTATdoc]

Nearly 30 month median survival is a new benchmark for met CRC, with some pts free of disease after surgery at 5 years. Comforting news